# A Study to Demonstrate Bioequivalence Between 6 x 2 mg Tablets of Perampanel and a Single 12 mg Tablet of Perampanel in Healthy Subjects

> **NCT01240187** · PHASE1 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 22 (actual)

## Conditions studied

- Partial Onset Epilepsy

## Interventions

- **DRUG:** perampanel
- **DRUG:** perampanel

## Key facts

- **NCT ID:** NCT01240187
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2013-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01240187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01240187, "A Study to Demonstrate Bioequivalence Between 6 x 2 mg Tablets of Perampanel and a Single 12 mg Tablet of Perampanel in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01240187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*